Hansa Medical Year-End Report 2016
Year-End Report 2016 – Business highlightsOctober-December in brief · Swedish Phase II study successfully completed with lead candidate IdeS in sensitized kidney transplantation patients · Application for EU Orphan Drug Designation for IdeS received positive opinion from EMA and the designation was formally granted by the European Commission in January 2017 · First patient treated with IdeS in US and EU multicenter Highdes study in highly sensitized kidney transplantation patients · Phase II study in asymptomatic patients with Thrombotic Thrombocytopenic Purpura (TTP) was